Gland Pharma Limited — Updates, 04-11-2024: Press Release

Gland Pharma reported Q2 FY25 financial results with a revenue of ₹14,058 million, up 2% YoY. EBITDA was ₹2,961 million, an 8% decrease YoY, resulting in a 21% EBITDA margin. Base business revenue rose by 5% to ₹10,659 million, maintaining a 34% EBITDA margin. The USA market showed a 3% revenue increase, while future growth plans include new market entries and a strategic partnership in biologics with Dr. Reddy's Laboratories.